Literature DB >> 32232976

CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19).

Pengfei Sun1, Xiaosheng Lu2, Chao Xu1, Yanjin Wang3, Wenjuan Sun4, Jianing Xi5.   

Abstract

Coronaviruses are common human viruses and include the severe acute respiratory syndrome coronavirus (SARS-CoV), the middle east respiratory syndrome coronavirus and the SARS-CoV-2. Coronaviruses mainly bind to transmembrane receptor proteins on the human cell membrane through spike proteins (S-proteins), thus releasing the RNA of the virus into the interior of the host cell to cause an infection. In this article, we discuss the mechanism and production of cyclodextrin-soluble angiotensin-converting enzyme 2 (CD-sACE2) inclusion compounds in the treatment of SARS-CoV-2 infections by blocking S-proteins. On the basis of the current research evidence, we believe that CD-sACE2 inclusion compounds have the potential to treat COVID-19. We hope that our article can provide a theoretical basis for later experiments.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  2019-nCoV; ACE2; COVID-19; coronavirus; cyclodextrin

Mesh:

Substances:

Year:  2020        PMID: 32232976     DOI: 10.1002/jmv.25804

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  20 in total

Review 1.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

2.  Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.

Authors:  Rachel M Golonka; Piu Saha; Beng San Yeoh; Saurabh Chattopadhyay; Andrew T Gewirtz; Bina Joe; Matam Vijay-Kumar
Journal:  Physiol Genomics       Date:  2020-04-10       Impact factor: 3.107

3.  Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California.

Authors:  Samuel J S Rubin; Samuel R Falkson; Nicholas R Degner; Catherine A Blish
Journal:  J Clin Transl Sci       Date:  2021-06-01

Review 4.  Potential role of IFN-α in COVID-19 patients and its underlying treatment options.

Authors:  Lei Yang; Jianhui Wang; Pei Hui; Timur O Yarovinsky; Saiaditya Badeti; Kien Pham; Chen Liu
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-05       Impact factor: 4.813

5.  Pirfenidone: A novel hypothetical treatment for COVID-19.

Authors:  Soroush Seifirad
Journal:  Med Hypotheses       Date:  2020-06-17       Impact factor: 1.538

6.  National common metrics for the NIH Clinical and Translational Science Award Institutions: A signal of the transformation of the American biomedical research enterprise.

Authors:  Harry P Selker
Journal:  J Clin Transl Sci       Date:  2019-10-08

7.  Some Thoughts on the Impact of COVID-19 on Plastic Surgery.

Authors:  Pengfei Sun; Yanjin Wang; Huachang Sun; Fang Luan
Journal:  Aesthetic Plast Surg       Date:  2020-09-25       Impact factor: 2.326

Review 8.  Immune Response and COVID-19: A mirror image of Sepsis.

Authors:  Eduardo López-Collazo; José Avendaño-Ortiz; Alejandro Martín-Quirós; Luis A Aguirre
Journal:  Int J Biol Sci       Date:  2020-07-09       Impact factor: 6.580

Review 9.  SARS-CoV-2: is there neuroinvasion?

Authors:  Conor McQuaid; Molly Brady; Rashid Deane
Journal:  Fluids Barriers CNS       Date:  2021-07-14

10.  Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19".

Authors:  Shuaishuai Hu
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.